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The primary objective of this study was to determine if Porcine Respiratory 
Coronavirus (PRCV) sensitized gilts responded to intranluscular (IM) vaccination with 
Transmissible Gastroenteritis Virus (TGEV) in a similar fashion as gilts sensitized to 
TGEV alone. It was demonstrated that pregnant gilts sensitized to PRCV, prior to TGEV 
vaccination, do not produce significantly higher TGEV serum neutralizing r ~ t i b ~ d y  titers 
when compared with gilts sensitized to either PRCV or TGEV alone, Anti-TOEV IgG and 
IgA levels were assayed for in post-farrow milks from all gilt groups. Only IgG was 
detected which indicated a lack of rnucosal priming. The second objective of this study was 
to determine if animals, which have recovered from a TGEV infection, can be infected with 
PRCV. TGEV antibodies circulating in these exposed piglets prevented PRCV infection as 
demonstrated by the absence of PRCV shedding during the post-challenge period. I t  was 
found that these piglets had an eight-fold boost in TGEV serum neutralizing antibody titers 
21- days post PRCV challenge. Piglets that had not been exposed to TGEV significantly 
shed virus during this same post-challenge period and exhibited a three-fold boost in TGEV 
neutralizing antibody titer. Piglets that had suckled TGEV immune dams were also, for the 
most part, protected from PRCV shedding but exhibited no boost i n  TGEV serum 
neutralizing antibody titer. 
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INTRODUCTION AND REVIEW OF LITERATURE 
Transmissible Gastroenteritis Virus (TGEV) is a coronavirus that infects swine of 
all ages. It replicates in the cytoplasm of absorptive epithelial cells located in the villi of the 
small intestine (14). Virus infection occurs orally and the virus is shed in the feces and in 
respiratory secretions of infected animals. TGEV appears in two clinical forms: epizootic 
and enzootic (8,9). In its epizootic form, TGEV replication results in a degeneration or 
shortening of the small intestinal villi decreasing its absorptive capability. This villus 
atrophy results in severe watery diarrhea which causes piglets to die of dehydration during 
the frst two weeks of age. In the enzootic, or chronic form, persistent infection of a herd 
with TGEV is a direct result of continual or frequent introduction of susceptible animals 
into the immune or partially immune herd. Therefore, the disease is perpetuated from 
infected animals to susceptible animals (9, 19). TGEV diarrhea in its chronic f o m  usually 
occurs in piglets older than two weeks of age and can persist through two weeks post- 
weaning. TGEV is considered the prototypical enteropathogenic virus and is often used in 
models to study pathophysiology and pathogenesis of viral diarrhea(l4). 
Unlike humans, pigs cannot transfer immunoglobulins (Ig) transplacentally. 
Therefore, at birth piglets are devoid of Igs which are then subsequently obtained by 
suckling milk from an immunized dam. Passive immunity is achieved by ingestion of milk 
antibody providing the neonate with the same complement of antibodies as the dam (1 8). 
This ability to ingest high levels of colostral Ig is essential to the piglet's survival. There are 
three classes of Igs found in sows milk: IgG, IgM and IgA. IgG is the most abundant Ig in 
the colostrum accounting for 80% of the total Ig content (16). Within the first week of 
lactation, the concenuation of IgG decreases 30-fold (1 8). IgM accounts for 5% of the total 
Ig in colostrum which makes it the least abundant of the three classes (1 6). After three days 
of lactation, IgM is usually undetectable (19). IgA antibodies (Abs) provide optimal passive 
immunity to TGEV because concentrations decline only 3-fold during the first week of 
lactation becoming the predominant milk Ig and providing the most effective protection. 
Reasons why IgA has greater efficacy than the other two Igs include 1). they are found at 
higher levels than the other Igs, 2). they are resistant to intestinal proteolytic enzymes, and 
3).they bind to the gut enterocytes. Even though piglets do not absorb secretory IgA, its 
presence is still important in passive immunity. Pensaert and others have reported that pigs 
which have recovered from TGEV infection can uansfer passive protection to their suckling 
piglets by the frequent ingestion of colostrum and milk that contain TGEV-neutralizing 
Abs. These Abs neutralize the virus in the lumen of the intestine preventing the virus from 
infecting susceptible epithelial cells. Haelderman termed this process "lactogenic 
immunity". Since secretory IgA is produced in mammary tissue by cells seeded from the 
intestine, this "gut-mammary" association is important in designing vaccination programs 
in which lactogenic immunity is utilized (1 8). 
Since IgA is produced by a lactating sow as a consequence of an intestinal 
infection, it is advantageous that pigs be immunized orally as well as intramuscularly (IM). 
When pigs are immunized IM only, a circulatory IgG antibody response is produced which 
provides most of its protection systemically, not intestinally. Although a lactating sow 
immunized IM may offer some protection to her piglets during the first week of life, it is 
not lasting due to at least a ten-fold drop of IgG antibody 48 hours after farrowing (20). 
This results in IM immunization not being the most effective route for protection of 
suckling piglets in that there is little or no gut immunity to TGEV during lactation. Rut if 
the sow is immunized orally, the gut's active immunity stimulates IgA lymphocytes (4). 
These IgA producing lymphocytes migrate to the mammary gland resulting in local IgA 
production (1 1). In lactating sows, this IgA is longer-lasting (decreasing 3-fold vs IgG's 
30-fold in one week) and protective when it  is continually ingested by the piglets. 
Intramuscular inoculation with TGEV (virulent or attenuated) during the gestation of swine, 
who hsve been previously primed orally with TGEV, result in a boost in milk Ab's of both 
IgG and IgA classes. Therefore, if a sow is vaccinated IM only, her piglets do not absorb 
the longer lasting, protective milk IgA and become sick when infected with TGEV. This is 
because TGEV antibodies (IgA) are at a low level leaving only IgG antibodies, which do 
not provide optimal protection (19). With these things in mind, the best vaccination 
program for a pregnant dam must involve both an oral route, to stimulate the production of 
IgA, and an IM route, to stimulate IgG and boost IgA production. Without oral stimulation, 
a less effective antibody response is produced. 
Ambico, Inc. has developed an oral vaccine against TGEV which takes into 
account the biology of Igs mentioned above. The vaccine is administered both orally and 
intramuscularly assuring that higher and more persisting TGEV milk antibody levels are 
produced. This is accomplished by the vaccine virus multiplying in the sow's oral- 
pharyngeal cavity at which point the primed lymphocytes migrate towards the Peyer's 
patches. Here, in the ileum of the small intestine, the lymphocytes continue to differentiate 
and stimulate the production of IgA lymphocytes. These lymphocytes migrate to the 
supramammary lymph nodes and secrete IgA antibodies into the milk which allows enteric 
protection of the suclding piglets fiom virulent TGEV challenge (20). Therefore, this 
vaccine protects piglets via passive immunization rather than active immunization in that 
active immunity involves the developnlent of hurnoral immunity in response to stimulation 
by antigen (10). 
A TGEV serological survey was done in Belgium among a sow population. Sixty 
eight percent of these animals exhibited an unexpectedly high incidence of antibodies 
against TGEV even though an increase incidence of diarrhea was not seen. No TGEV 
vaccination is performed in Belgium, so this finding could not be explained and indicated 
that a non-enteropathogenic virus related to TGEV had appeared. Following this discovery, 
the virus was isolated in both pigs and cell culture, Further studies indicated that this virus 
replicates in high titers in the tonsils tissues and the respiratory tract. Replication has also 
been found to occur in nasal, tracheal, bronchial, bronchiolar and alveolar epithelial cells 
and in alveolar macrophages (1). This virus was subsequently named Porcine Respiratory 
Coronavhs (PRCV). Despite all of the areas of replication, no enteric infection exists and 
even the respiratory tract infection is usually asymptomatic (3, 12, 13,23). Therefore, 
PRCV is spread through herds aerogenically. The behavior of TGEV and PRCV, even 
though they produce different pathology, are closely related antigenically. Porcine 
Respiratory Coronavirus induces antibody responses in pigs that cannot be distinguished 
from TGEV infection via standard seroIogical assays (3). In 1990, Rasschaert et al. found 
that PRCV contained a 224 amino acid deletion in the S, or spike, glycoprotein which was 
not seen in TGEV (17). The S glycoprotein is one of three structural proteins (the others 
are membrane and nucleoprotein) of TGEV and PRCV and is responsible for the induction 
of neutralizing antibodies (7). Using these antigenic differences, specific monoclonal 
antibodies have been developed to distinguish between these two viruses and their 
antibodies (3). 
Porcine Respiratory Coronavirus has aIso been detected in the United States and 
was first isolated by Dr. Howard Hill in 1989 at the Veterinary Medical Research Institute 
in Ames, Iowa. This isolate was obtained from a pig nasal swab sent to Dr. Will from an 
Indiana herd. The virus was propagated in swine testicular cells and designated 1SU-1 (1). 
using the PRCV-TGEV differentiating monoclonal antibodies mentioned previously, this 
PRCV isolate has been found to be similar, but not identical, to those found in Europe. 
Further studies have indicated a 227 amino acid deletion in the S glycoprotein which differs 
from the 224 amino acid deletion seen in European PRCV (22). 
A decrease was seen in clinical TGEV infections in Europe at approximately the 
same time that seroconversion (4-fold increase in serum neutralizing antibody titers) to 
PRCV was detected in swine and has led researchers to speculate whether pregnant animals 
that have been sensitized to PRCV will protect their piglets from TGEV infections (13). 
Studies done at Ambico, Inc. have determined that piglets inoculated orally and intranasally 
with PRCV, followed by an oral TGEV challenge 14-days later, developed watery diarrhea 
within 48 hours post-challenge. This reaction mimicked symptoms seen in non-inoculated 
controls challenged at the same time. Morbidity rates for all animals, including non- 
inoculated controls, ranged from 42 to 50% while piglets vaccinated orally with TGEV 
remained clinically normal post-challenge. This study indicated that piglets previously 
exposed to PRCV will not be protected from virulent TGEV. A similar study has been 
published using the European PRCV confirming the above results (1 3). Antigen 
sensitization at the respiratory level results in ehe production of IgG as the predominant Ig 
class, therefore, protection on the enteric level is not lasting (1 3). If piglets that have 
suckled PRCV positive sows were challenged with virulent TGEV at three days of age, 
they would be protected since there are still protective IgG antibodies in the piglet's gut. 
But if the piglets were challenged at seven days of age, they would not be protected due to 
the rapid decrease in IgG by that time. This is another indication ehat PRCV is not a good 
candidate for a vaccine against TGEV because it  does not elicit long lasting IgA antibodies. 
Nonetheless, previously published reports have indicated that PRCV can induce the 
secretion of IgA antibodies in milk and that these antibodies have the capacity to neutralize 
TGEV (15). Other studies report that natural infection with PRCV induces protective 
lactogenic immunity against TGEV(2,6). These studies, as well as others, have continued 
the speculation as to whether PRCV- infected gilts can passively protect their piglets from 
TGEV infection. This resexch wilt determine whether gilts sensitized with PRCV will 
respond to vaccination with TGEV in a similar fashion to that of sensitized gilts. IgG and 
IgA levels will be determined from colostra, seven, and fourteen day post-farrow milits. 
The second objective will determine if animals that have recovered from a TGEV infection 
can be subsequently infected with PRCV. 
MATERIALS AND METHODS 
Animals 
Fourteen pregnant gilts were purchased from H + K Enterprises of Ames, Iowa, 
and were delivered nine weeks pre-farrow. These gilts were screened for anti-TGEV 
antibodies and all were sero negative. The PRCV exposed gilts were kept separate from the 
other animals in the study and strict isolation procedures were applied to avoid aerosol 
spread of virus. 
Viral inocula 
Porcine Respiratory Coronavirus ISU-l/ST-7 virus isolate was obtained from Dr. 
Howard Hill of the Veterinary Medicine Research Institute in Ames, Iowa. It was passed in 
swine testicular (ST) cells seven times and its titer was determined to be 109.0 TCID5O/rnl. 
The TGEV vaccine used was Ambico's Prosystem 1 serial #614 (Ambico, Inc. 
Dallas Center, Iowa) which had a titer of 107+3 TCID5O/ml. 
Virulent TGEV Standard Challenge (SC) lot-4 was prepared by infecting 
gnotobiotic piglets with virulent TGEV. Upon the first signs of clinical infection, the 
piglets were sacrificed and the small intestinal contents collected as a 50% extract. The 
contents are free of pathogenic bacteria. By titrating the isolate in susceptible piglets, a Pig 
Infectious Dose level was determined. In this study, 1000 Pig Infectious Doses (PID's) per 
baby pig were used for challenge. 
Vaccination of Gilts 
Eight of the fourteen gilts (designated groups A and B) were inoculated with PRCV 
at eight weeks pre-farrow which allowed them sufficient time to recover from infection. 
The dosage was given I ml orally in a corn-milk mash and 2 ml given intranasally using an 
atomizer in order to split the dose equally between nares during inspiration. 
Four of the PRCV infected gilts (group A) and two others not infected with PRCV 
(group C) were given an IM vaccination with TGEV-Rotavirus vaccine at five and two- 
weeks pre-farrow. The vaccine used was a single dose with each individual vial being 
reconstituted with 2 ml of sterile diluent prior to use. 
The remaining four gilts served as non-vaccinated controls (designated groups D 
and E). 
Refer to Table 1 for a summary of gilt vaccinations. 
Gilt Sample Collection and Testing Parameters 
All gilts were bled at time of arrival, five-weeks pre-farrow, day of farrow, 
fourteen days post-farrow, and twenty-eight days post-farrow. Blood samples were 
altowed to clot, centrifuged at 1000 x g for 20 min, and the sera collected. The sera was 
then inactivated for 30 min at 56O C and assayed for TGEV serum neutralizing antibodies 
using a varying serum-constant virus assay. Fifty to five hundred TCID501s of indicator 
virus were used to determine anti-TGEV titers. In a 96-well microtiter plate, senlm 
dilutions were incubated with the amount of indicator virus mentioned above, at 2 j 0  C for 
2 hours. Following incubation, 100,000 ST cells per well were added to the serum-virus 
mixture. The plates were incubated at 370 C for three days. The serum neutralization titers 
were calculated using a Spearman-Karber 50% Endpoint Table. 
Colostra and milks were collected at time of farrow, seven days post-farrow, and 
fourteen days post-farrow. The samples were centrifuged and the milk collected below the 
top layer of fat. Following heat inactivation for 30 min at 560 C, the colostra and milk were 
assayed for TGEV serum neutralizing antibodies as previously described. 
After the colostrum and milk neutralization titers were calculated using the 
Spearman-Karber 50% Endpoint Table, they were assayed for IgG and IgA 
immunoglobulin content against TGEV. This was done using an indirect ELISA system in 
which 96-well Imrnulon - 2 ELISA plates were coated with TGEV antigen and ST cell 
lysate. The antigen was propagated in tissue culture, cell debris removed via low speed 
centrifugation, and concentrated l0Ox via high speed centrifugation, The cell lysate was 
prepared by first removing the cells from a confluent roller bottle by freezing and thawing. 
The cell debris was removed via low speed centrifugation and the supernatent collected. 
This was concentrated 100 x via high speed centrifugation. Every other row of wells were 
coated with a predetermined dilution of TGEV antigen while the rest of the wells were 
coated with the same dilution of cell Iysate. The plates were incubated at 4OC overnight. 
After blocking for two hours at room temperature using PBS/O.05% Tween 20/1% bovine 
serum albumin, test colostrum and milk samples were added, diluted as desired, and 
incubated at 250 C. After washing the plates, a solution of IgG and/or IgA anti-swine 
antibodies conjugated with horse radish peroxidase was added to detect IgG and IgA 
levels. Following incubation and washing, a 2,2'-azino-di-[3-ethylbenzthiazoline 
sulfonate](ABTS) substrate solution was added and allowed to develop. Plates were read at 
405 nm on an ELISA plate reader. Calculations were done by subtracting the readings 
obtained on the cell lysate dilutions from those obtained on the corresponding, virus- 
concentrate dilutions. This gave the ELISA specific reaction value. A value of 0.2 and 
higher was considered positive. 
Clinical Observations were made daily and litter score sheets were presented 
detailing the number of animals born alive and dead. Also, feces were scored as normal, 
creamy or watery. 
TGEV and PRCV Piglet Chalienges 
Baby pigs in groups B, C and D were orally challenged with 103.0 PIDts of 
virulent TGEV standard challenge lot-4 at fourteen days of age. 
At time of weaning (28 days of age), piglets in groups A, D and E, were challenged 
1.0 ml orally and 1.0 rnl inwanasally (0.5 rnl/nare) with PRCV. 
Refer to Table 1 for a summary of piglet challenges, 
Piglet Sample Collection and Testing Parameters Post PRCV Challenge 
Blood samples were collected at time of challenge and 21 days post-challenge. They 
were processed as before and assayed for serum neutralizing antibodies to TGEV as 
described previously. Geometric mean titers of all groups were calculated by taking the log 
of each sample titer, averaging them, and then taking the antilog. 
Throat and nasal swabs were collected starting at five days post PRCV challenge 
and continuing through fifteen days post PRCV challenge. One swab was used for both the 
nose and throat. Following swabbing, the swab was placed in a test tube containing 1.5 rnl 
with 200 pg/ml gentamicin. The combination was centrifuged at 1000 x g for 20 
min. The liquid was expressed from the swabs on the side of the collection tube and an 
equal volume of 50% sucrose was added giving a final sucrose concentration of 25%. 
Swab samples were assayed for PRCV by plaque assay. This was done by infecting 
confluent ST  6-well microtiter plates with serially diluted swab samples. A Noble agar 
overlay was added to each well and incubated at 370C for three days. Following the 
incubation period, another Noble agar overlay with neutral red dye was added to each well 
and incubated at 37OC overnight. Plaques that were 1 rnm in diameter were observed and 
counted as positive (for presence of plaques) or negative (for absence of plaques). 
Refer to Table 1 for a compete summary of gilt and/or piglet vaccination, 
challenges, and data collection parameters performed in this study. 
Table 1. Gilt vaccination, piglet challenge and sample collection schedule 
Gilt treatment schedule Piglet treatment schedule 
Day of Throat and 
Test G r o u ~ s  Bleed Inoculate/Vaccinate Milk Challenge nasal swabs 
9 - w ~ ~  A, B, C, D, E X 
8-WPF A, B X(PRCV;OEII and  IN^) 
5-WPF A, B, C, D, E X 
A, C X(TGEV;IM~) 
2-WPF A, C X(TGEV;IM) 
D0F2 A, B, C, D, E X X 
~ - D P F ~  A, B, C, D, E X 
14-DPF A, B, C, D , E  X X 
B, C, D X(TGEV:oral) 
28-DPF A, B, C, D, E X 
A, D, E X X(PRCV;Oral+IN) 
5 throuph ~ ~ - D P w ~  fGrps A. D. E) X 
1. WPF = Weeks Pre-Farrow 
2. DOF = Day of Farrow 
3. DPF = Days Post-Farrow 
4. DPW = Days Post-Weaning 
5. IN = Inuanasal 
6. IM = Intramuscular 
Statistical analysis 
Student's T test was used to compare data from between sow groups and piglet 
groups. 
RESULTS 
Effect of Sow Inoculations 
All sows had normal farrowings except for two. One sow had only one piglet 
which died two days later while the other sow killed three of its four piglets by not 
allowing them to suckle. None of the inoculated sows exhibited any signs of illness post 
PRCV inoculations or TGEV vaccinations. One sow from the non-vaccinated control group 
refused to eat for five days following TGEV challenge of piglets while one gilt from the 
PRCV group refused to eat for one day and developed a soft stool for one day following 
piglet challenge. This lack of appetite, from these sows, was thought to be an indication of 
TGEV infection. 
All TGEV neutralizing antibody titers for pre-vaccination sera, day of farrow sera 
and colostra, seven day post-farrow milks, fourteen day post-farrow sera and milks and 
twenty-eight day post-farrow sera, are shown in Table 2. All inoculated/vaccinated sows 
seroconverted (four-fold increase in antibody titer) to TGEV at the time of farrowing while 
the non-vaccinated controls remained seronegative for TGEV. All virus exposed groups 
had statistically significant (P < 0.05) colostral TGEV antibody titers compared with the 
non-vaccinated control group. All sera and milk titers decreased over time except for a 
dramatic jump in anti-TGEV titers seen in 28 day post-farrow sera of non-vaccinated, 
PRCV inoculated, and TGEV vaccinated sows. Piglets from these three gilt groups were 
challenged with TGEV at 14 days of age and subsequent virus shedding may have boosted 
the sows antibody titers. These boosts in antibody titers indicate an infection took place and 
that the inoculations/vaccinations were not protective. This is further demonstrated in that 
TGEV vaccinated and PRCV inoculated sows exhibited a statistically significant (P < 0.05) 
increase in antibody titer compared to the non-vaccinated gilts. 
Table 2. Sow neuualizing antibody titers vs TGEV 
Inoculation Pre vaccination Day of farrow 7 D P F ~  14 DPF 28 DPF 
Animal # P ~ O U O  sera Sera Colostrum Milk Sera Milk Sera 
7 8 A~ 52.0 5 7 299 2.0 21 2 NS 
79 2.8 197 452 86 NS NS NS 
84 52.0 49 260 11.3 22.7 5.7 NS 
87 12.0 86 393 22.7 16 12.0 11.3 
90 D + E ~  1 2  .o 12.0 12.0 12.0 12.0 12.0 37 
92 12.0 12.0 12.0 12.0 12.0 52.0 22.7 
89 1 2  '0 52.0 52.0 52.0 12.0 12.0 NS 
138 52.0 12.0 12.0 12.0 52.0 52.0 12.0 
1. DPF = Days Post Farrow 
2. Group A Vaccination: PRCV - 109.5 TCIDc,o/ml; 1 ml oral + 2 ml IN(8-WPF) 
TGEV- 107.6 TCIDc,o/ml; 2 ml IM (5 + 2-WPF) 
3. NS = No Sample 
4. Group B Vaccination: PRCV - 109.5 TCIDc,o/ml; 1 ml oral + 2 ml IN(8-WPF) 
5. Group C Vaccination: TGEV- 107.6 TCID50/ml; 2 ml IM (5 + 2-WPF) 
6. Group D + E Vaccination: Non-Vaccinated Controls 
All of the sow colostrum and milk samples were evaluated for IgG and IgA type 
immunoglobulins. Table 3 shows that all inoculations (TGEV, TGEVPRCV, and PRCV) 
stimulated IgG responses, which significantly decreased by 7 days post-farrow. The 
strongest IgG responses were seen in the PRCVlTGEV and TGEV only groups. No 
detectable IgA responses were seen in any colostra or milk samples. 
Table 3. IgG and IgA TGEV neutralizing antibody levels in sow colostra and milks 
Inoculation D O F ~  Colosmm 7 D P F ~  Milk 14 DPF Milk 
Animal # PTOUD IeG Ig A I eG I e A  IgG IEA 
90 D + E ~  510 _<lo 110 510 110 510 
92 110 510 110 110 510 510 
89 210 510 110 110 110 110 
138 510 510 510 510 510 510 
1. DOF = Day of Farrow 
2. DPF = Days Post-Farrow 
3. Group A Vaccination: PRCV - 109.5 TCID5o/ml; 1 ml oral + 2 ml IN(8-WF) 
TGEV- l ~ ~ . ~  TCID5o/ml; 2 ml IM (5 + 2-WPF) 
4. NS = No Sample 
5. Group B Vaccination: PRCV - 109.5 TCID5o/ml; 1 ml oral + 2 ml IN(8-WF) 
6. Group C Vaccination: TGEV- 107-6 TCID5o/ml; 2 ml IM (5 + 2-WPF) 
7. Group D + E Vaccination: Non-Vaccinated Controls 
Effect of TGEV and/or PRCV Challenge on Piglets 
All the piglets from sow groups B, C, and D were challenged at 14 days of age with 
TGEV. All piglets exhibited creamy to watery diarrhea that persisted four to seven days. 
Piglets from group C gained nearly twice the weight of the group B piglets while group D 
piglets lost weight (data not shown). 
All piglets from sow groups A, D, and E were challenged at 28 days of age with 
PRCV. None of the piglets exhibited clinical respiratory signs at any rime during the 21- 
day post-challenge period. Piglets from groups A gilts did not significantly shed PRCV 
post-challenge. Piglets from group D gilts, also challenged at 14 days of age with TGEV, 
did not shed PRCV during the post-challenge period. Thirteen out of seventeen piglets 
from group E gilts shed PRCV 7 days post-challenge, decreasing significantly 8 days post- 
challenge. See Table 4 for data. 
Table 4. PRCV Isolation from nasal and throat swabs 
Virus shedding post PRCV challenge 
Inoculation Inoculation(s) nasal and throat swab isolations 
gf gilts of piglets 7 - D P C ~  8-DPC 9-DPC 
Uninoculated TGEV(O)/PRCV(IN-o)~ 011 6 0116 0116 
Uninoculated PRCV(IN-0$ 13/17 1/17 0117 
1. DPC = Days Post-Challenge 
2. Piglets were challenged 2 rnl orally with 103.0 P I D ~ o  f TGEV at 14 days post farrow with 1 rnl oral 
and 1 rnl intranasally with 109e3 TCID50lml of PRCV at 28 days post-farrow. 
3,Pigets were challenged 1 rnl oral and 1 ml inuanasnlly with PRCV 109.3 TClD501ml of PRCV at 28 
days post-farrow. 
Day of PRCV challenge and 21-day post-challenge sera were assayed for 
neutralizing TGEV antibodies for all the previously mentioned piglets. All PRCV 
challenged piglets that suckled group A sows exhibited no increase in anti-TGEV titers. 
PRCV challenged piglets that suckled group D sows, and were challenged 14 days of age 
with TGEV, exhibited an eight-fold average increase in anti-TGEV titers by 21 days post 
PRCV challenge. Piglets that suckled group E sows, exhibited a three-fold average increase 
in anti-TGEV titers by 21-days post PRCV challenge. All data are shown in Table 5. 
Table 5 . Piglet serum neutralizing antibodies vs TGEV 
fnocuhlions Piglet serum virus titer 
1 
-
4- 1 Uninoculated TGEV(O)IPRCV(O-IN)~ 43 227 
4-2 33 33 
4-3 28 260 
44 1 2  .O 130 
4-5 11.3 86 
4-45 43 209 
4-7 4 3 343 
4-8 32 149 
12-1 52.0 149 
12-2 32 227 
12-3 49 N S ~  
124 25 98 
12-5 22.7 NS 
1216 22.7 NS 
12-7 98 343 
12-8 49 260 
12-9 22.7 NS 
5-1 PRCV(0-IN)/TGEV(IM) PRCV(O- IN)^ 22.7 19 
5 -2 16 19 
5-3 32 19 
5 4  19 5.7 
5-5 2 1 8.0 
5-45 22.7 37 
5-7 16 4 .O 
5-8 16 5.7 
5-9 16 11.3 
10-1 7 5 43 
10-2 130 2 1 
104 86 28 
10-5 75 2 1 
104 57 25 
10-7 86 25 
10-8 37 16 
10-9 49 2 1 
11-2 260 19 
11-4 86 25 
11-5 2 8 <2.0 
11-7 3 3 2 5 
1. DPC = Days Post PRCV Challenge 
2. Piglets were challenged 2 rnl orally with l03.O P I D ~ o  f TGEV at 14 days of age and 1 rnl on1 and 1 ml 
inaanasalIy with TCID50/rril of PRCV at 28 days of age. 
3. NS = No Sample 
4. Pigets were challenged 1 rnl oral and 1 ml inwanasally with PRCV logs3 TCID50/ml of PRCV at 28 
days of age. 
Table 5 . Piglet serum neutrafizing antibodies vs TGEV (Cont.) 
Inoculations Piglet serum virus titer 
Animal # Gilts Piglets Day of PRCV Challcn~e 21 D P C ~  
6- 1 Uninwulated PRCV(O- IN)^ 12.0 2.8 
6-2 52.0 12 .O 
6-3 12.0 I6 
6-4 12.0 <2 .O 
6-5 52.0 2.8 
6-6 52 .O 4 .O 
6-7 S2.0 8 .O 
6-8 22.0 2.8 
7- f 52 .O N S ~  
7-2 1 2  '0 4 .O 
7-3 12 -0 52.0 
7 4  52 .o 4 .o 
7-5 52 .o 5.7 
7-6 <2 .O NS 
7-7 1 2  .O 52 .o 
7-9 <2,0 12.0 
1. DPC = Days Post PRCV Challenge 
2. Piglets were challenged 2 rnl orally with 103.O PlDso of TGEV at 14 days of age and I ml on1 and 1 rnl 
inuanasally with 109.3 TCIDjg/ml of PRCV a1 28 days of age. 
3. NS = No Sample 
4. Piglets were challenged 1 rnl oral and 1 rnl in~anasally with PRCV 109.3 TCID5dml of PRCV at 28 
days of age. 
DISCUSSION 
It has been thought by Coronavirus researchers that PRCV may be a suitable candidate for 
vaccination against TGEV infection (13). Publications have suggested PRGV may multiply 
in the gut and elicit TGEV neutralizing antibodies (5). It has been reported that pregnant 
sows (or gilts) exposed at the gut level to virulent TGEV will secrete TGEV neutralizing 
IgA antibodies in their milk (lactogenic immunity) (20). Fitzgerald et. al. have 
demonstrated that these animals can be boosted parenterally and in  subsequent farrowings 
reproduce IgA levels seen in the initial infection. Therefore, it was decided to use this 
pregnant sow model to determine if PRGV recovered animals, boosted parenterally against 
TGEV, would respond in a similx fashion as those that had been primed with TGEV only. 
One of the parameters used was to evaluate IgG and IgA irnunogiobulin levels 
produced in colostrum, seven and fourteen day milks. The four groups used were non- 
vaccinated controls, animals exposed to PRCV, animals vaccinated IM with TGEV, and 
animals which had recovered from PRCV infection and subsequently boosted IM with 
TGEV. Serum and milk neutralizing titers to TGEV were evaluated and no TGEV 
neut~alizing titers were detected in the non-vaccinates. Neutralizing titers in colostra and 
sow sera had similar antibody levels and were not f o u ~ ~ d  to be significantly different 
between the PRCV and the PRCVEGEV-IM groups (Table 2). Fourteen day milks were 
not significantly different between the three groups but were found to drop in titer 10-fold 
when compared to the colostra, suggesting an IgG type response. When these colosrra and 
milks were evaluated for TGEV IgA, none was found (Table 3). These data demonstrate 
that PRCV does not significantly replicate in the proper tissues to allow for an IgA type 
secretion. This IgA secretion is important in considering a virus isolate as a vaccine 
candidate for the prevention of TGEV infections. All vaccinated groups had good TGEV 
IgG responses with the highest levels being observed in the TGEV-lM vaccinated group 
followed by the PRCVITGEV-IM group and PRCV group, in descending order. Due to 
the high levels of IgG seen in the TGEV-IM group, relatively low levels of IgG were 
detected in seven-day milks whereas in all other groups, IgG levels were undetectable with 
the exception of one animal in the PRCVEGEV-IM group. An increase in TGEV 
neutralizing antibodies was observed in some of the 28-day post-farrow sow sera. This 
was due to the fact that their litters were challenged with virulent TGEV and it became 
apparent that the sows themselves became exposed, thus further suggesting that the sows 
themselves were not protected from virulent TGEV by the viruses or routes used. 
Litters from the non-vaccinated controls, TGEV-IM and PRCV groups were 
challenged at fourteen days of age with virulent TGEV. All animals developed a creamy to 
watery diarrhea that persisted for four to seven days. No protection was observed in any 
of these animals when compared to challenged piglets that were nursing non-vaccinated 
controls. 
Using this sow model it was demonstrated that PRCV is not a good vaccine 
candidate for TGEV infections because an IgA type of antibody response was not 
produced, no passive protection was observed, and immunized sows themselves became 
infected. This phenomenon is similar to what happens when TGEV is administered 
parenterdly (8). Without oral priming, antigen is not presented to the proper rnucosal 
surfaces (Ryers patches) resulting in a systemic immunity that is not protective at the gut 
(mucosal) level. 
Our data suggest that BRCV does not multiply at the gut level, therefore it  is 
hypothesized that this v i m  is a strict respiratory pathogen. In order to more fully 
understand the mechanisms of protection via trafficking lymphocytes, it was decided to 
investigate whether gut level exposure to TGEV would confer protection to PRCV 
(respiratory) infections. Additionally, it was thought that if PRCV is solely a respiratory 
infection, protection shouId be seen in the piglets suckling PRCV or PRCV/TGEV-IM 
exposed gilts. The reason for this is that within the first 24-hours of birth, nursing piglets 
absorb, via the colostrum, IgG antibodies which will eventually enter the bloodstream and 
circulate systemically. 
What was of interest was determining whether these type of antibodies would be 
protective when comparing piglets that had not suckled PRCV exposed gilts to piglets (who 
had also not suckled from PRCV exposed gilts) that had recovered from a virulent TGEV 
infection. This was demonstrared by inoculating these groups of piglets, along with piglets 
which had suckled from PRCVlTGEV exposed gilts, with PRCV. Piglets which suckled 
PRCVEGEV positive dams and piglets (who had suckled from non-vaccinated dams) that 
had recovered from a virulent TGEV infection did not significantly shed virus during the 
post-challenge period. On the other hand, piglets which had si~ckled from non-vaccinated 
dams, significantly shed virus up to seven days post-challenge. This clearly demonstrates 
that piglets acquiring TGEV antibodies, actively or passively, will be protected from a 
PRCV infection. This protection also confms  our hypothesis that PRCV is a strict 
respiratory pathogen and that gut level exposure does confer protection against respiratory 
infections. 
Since exposure to TGEV protects against PRCV infection, it was wondered if this 
subsequent exposure to PRCV would have any anti-TGEV booster effect. Piglets that had 
suckled from non-vaccinated gilts and had recovered from a TGEV infection prior to PRCV 
exposure, all had an average increase in anti-TGEV titers of eight-fold while piglets that 
had also suckled from non-vaccinated gilts had an average increase in anti-TGEV titers of 
three-fold. Piglets that had suckled from BRCVEGEV gilts did nor show any increase in 
anti-TGEV titers. This data show that TGEV vaccination is enhanced by exposure to 
PRCV. This is of particular interest in that PRCV continues to spread across the United 
States, Canada, and Europe. 
In this study, and others previously done (211, it has been shown that prior PRCV 
hfection does not protect against TGEV virulent virus challenge. This is due mainly to the 
fact that PRCV is a respiratory pathogen and does not replicate in gut mucosal surfaces. 
This lack of gut mucosal priming results in the absence of long lasting, protective, 
neutralizing IgA antibodies which can be passed on to suckling piglets. What would also be 
missing would be the ability to boost this antibody response with a parenteral vaccination. 
This study further demonstrated that passive or active acquisition of TGEV antibodies, 
protect against PRCV infection. The class of antibodies that conferred this protection were 
of the circulating IgG type. Finally, it was shown in this study that TGEV antibodies are 
significantly boosted following exposure to PRCV. This fact may be of interest when more 
TGEV vaccines are developed, tested, and/or improved in the future. 
CONCLUSIONS 
Three conclusions can be made from this study. First, this study demonstrated that 
prior PRCV infection does not protect against TGEV virulent virus challenge. Second, it 
was shown that passive or active acquisition of TGEV antibodies protect against PRCV 
infection. Finally, it was observed that TGEV antibodies are significantly boosted 
following exposure to PRCV. 
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